← Jazz Pharmaceuticals plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $366.0m | $386.0m | $309.6m | $637.3m | $1.1b | $591.4m | $881.5m | $1.5b | $2.4b | $1.4b | |
| Inventory, Net | $34.1m | $43.2m | $53.0m | $78.6m | $95.4m | $1.1b | $714.1m | $597.0m | $480.4m | $417.0m | |
| Assets, Current | $748.1m | $968.3m | $1.2b | $1.6b | $2.8b | $2.6b | $2.6b | $3.4b | $4.6b | $4.2b | |
| Property, Plant and Equipment, Net | $107.5m | $170.1m | $200.4m | $131.5m | $127.9m | $256.8m | $228.1m | $169.6m | $173.4m | $199.9m | |
| Goodwill | $893.8m | $947.5m | $927.6m | $920.0m | $958.3m | $1.8b | $1.7b | $1.8b | $1.7b | $1.8b | |
| Intangible Assets, Net (Excluding Goodwill) | $3.0b | $3.0b | $2.7b | $2.4b | $2.2b | $7.2b | $5.8b | $5.4b | $4.8b | $4.4b | |
| Operating Lease, Right-of-Use Asset | — | — | — | $139.4m | $129.2m | $86.6m | $73.3m | $65.3m | $53.6m | $58.9m | |
| Other Assets, Noncurrent | $14.1m | $16.4m | $42.7m | $47.9m | $25.7m | $40.8m | $55.1m | $67.5m | $114.5m | $99.0m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $234.2m | $224.1m | $263.8m | $356.0m | $396.5m | $563.4m | $651.5m | $705.8m | $716.8m | $830.7m | |
| Accrued Liabilities, Current | $193.3m | $198.8m | $264.9m | $267.9m | $352.7m | $666.3m | $803.3m | $793.9m | $910.9m | $1.0b | |
| Assets | $4.8b | $5.1b | $5.2b | $5.5b | $6.5b | $12.3b | $10.8b | $11.4b | $12.0b | $11.7b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $12.7m | $14.5m | $15.4m | $15.6m | $19.0m | $14.3m | $14.3m | |
| Accounts Payable, Current | $22.4m | $24.4m | $40.6m | $47.5m | $26.9m | $100.3m | $90.8m | $102.8m | $77.9m | $122.1m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $151.2m | $140.0m | $87.2m | $71.8m | $59.2m | $38.9m | $50.9m | |
| Deferred Revenue, Current | $1.1m | $8.6m | — | — | — | — | — | — | — | — | |
| Deferred Revenue, Noncurrent | $2.6m | $16.1m | — | — | — | — | — | — | — | — | |
| Long-term Debt, Excluding Current Maturities | $2.0b | $1.5b | $1.6b | $1.6b | $1.8b | $6.0b | $5.7b | $5.1b | $6.1b | $4.3b | |
| Long-term Debt, Current Maturities | $36.1m | $40.6m | $33.4m | $33.4m | $246.3m | $31.0m | $31.0m | $605.0m | $31.0m | $1.0b | |
| Liabilities, Current | $257.4m | $293.9m | $345.5m | $364.5m | $653.7m | $809.3m | $933.2m | $1.5b | $1.0b | $2.2b | |
| Deferred Income Tax Liabilities, Net | $556.7m | $383.5m | $309.1m | $224.1m | $130.4m | $1.3b | $944.3m | $847.7m | $676.7m | $594.5m | |
| Other Liabilities, Noncurrent | $112.6m | $176.6m | $218.9m | $109.4m | $101.1m | $117.0m | $106.8m | $104.8m | $86.6m | $124.5m | |
| Deferred Tax Liabilities, Net | $541.7m | $348.9m | $251.2m | $2.7m | $130.4m | $989.4m | $568.1m | $369.9m | $116.5m | $594.5m | |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, Issued | $6k | $6k | $6k | $6k | $6k | $6k | $6k | $6k | $6k | $6k | |
| Retained Earnings (Accumulated Deficit) | $528.9m | $918.0m | $841.0m | $1.1b | $1.2b | $830.2m | $733.6m | $878.7m | $1.1b | $646.2m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($317.3m) | ($140.9m) | ($197.8m) | ($223.4m) | ($134.4m) | ($400.4m) | ($1.1b) | ($842.1m) | ($947.7m) | ($568.6m) | |
| Additional Paid in Capital, Common Stock | $1.7b | $1.9b | $2.1b | $2.3b | $2.6b | $3.5b | $3.5b | $3.7b | $3.9b | $4.2b | |
| Stockholders' Equity Attributable to Parent | — | $2.7b | $2.8b | $3.1b | $3.7b | $4.0b | $3.1b | $3.7b | $4.1b | $4.3b | |
| Liabilities and Equity | $4.8b | $5.1b | $5.2b | $5.5b | $6.5b | $12.3b | $10.8b | $11.4b | $12.0b | $11.7b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.